Supernus Pharmaceuticals Inc.
SUPN
NSD
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
32.16
USD
-0.65
(-1.98%)
Optionable: Yes Market Cap: 1,707 M 90-day average vol: 0
Previous close: 32.81 Open: 32.0 Bid: 35.56 Ask: 35.56
52 week range
0.00 0.00
Last updated: Monday 8th August 2022
Get Access to 1 Billion Usable Market data points IN YOUR EXCEL SHEETS WITH EASY TO USE EXCEL FUNCTIONS
Get started todaySearch for a stock
Are you?
Metrics
Valuation
Price per Sales TTM ($) | 3.71 |
Price per Book TTM ($) | 2.03 |
PE Ratio (TTM) | 24.20 |
Book Value per Share ($) | 15.24 |
5 Year PE Range11 |
Returns
7 Day Return | 2.10% | |
1 Month Return | 6.67% | |
3 Month Return | 21.96% | |
1 Year Return | 24.99% | |
3 Year Return | 12.21% | |
5 Year Return | -22.88% | |
YTD Return | 10.29% |
Risk
Financial Health
Technicals
RSI (14 Day) | 64.97 |
14 Day SMA ($) | 31.17 |
14 Day EMA ($) | 31.31 |
Money Flow Index | 34.05 |
Average True Range | 1.07 |
50 Day SMA ($) | 29.15 |
200 Day SMA ($) | 30.04 |
ADX | 31.29 |
MACD | 0.91 |
Growth
Free Cash Flow QoQ Growth | -92.92% |
Free Cash Flow YoY Growth | 0.00% |
Revenue YoY Growth | 0.00% |
EPS QoQ Growth | 860.00% |
Revenue QoQ Growth | -4.11% |
EPS YoY Growth | 0.00% |
Profitability
Chart
News
Supernus to Participate in Annual Cowen Health Care Conference
Yahoo Finance 3/2/2022
Supernus Pharmaceuticals, Inc. (SUPN) CEO Jack Khattar on Q4 2021 Results - Earnings Call Transcript
Seeking Alpha 2/28/2022
Supernus Pharmaceuticals reports Q4 results
Seeking Alpha 2/28/2022
Supernus Announces Preliminary Fourth Quarter and Full Year 2021 Financial Results
Yahoo Finance 2/28/2022
Supernus Pharmaceuticals Q4 2021 Earnings Preview
Seeking Alpha 2/27/2022
Sigilon Therapeutics Appoints Sarah Yuan, Ph.D., as Chief Technical Operations Officer
Yahoo Finance 2/22/2022
Supernus to Provide Preliminary Fourth Quarter and Full Year 2021 Financial Results and Host Conference Call on February 28, 2022
Yahoo Finance 2/22/2022
Supernus Receives Notice Assigning Early October 2022 PDUFA for SPN-830 Apomorphine Infusion Device NDA
Yahoo Finance 2/22/2022
Supernus (SUPN) Moves 5.7% Higher: Will This Strength Last?
Yahoo Finance 2/21/2022
Analysts Estimate Supernus Pharmaceuticals (SUPN) to Report a Decline in Earnings: What to Look Out for
Yahoo Finance 2/17/2022
Why the Earnings Surprise Streak Could Continue for Supernus (SUPN)
Yahoo Finance 2/9/2022
Lisanti Capital Growth, LLC Buys Saia Inc, Knight-Swift Transportation Holdings Inc, ...
Yahoo Finance 2/4/2022
Supernus Pharmaceuticals (NASDAQ:SUPN) investors are sitting on a loss of 18% if they invested three years ago
Yahoo Finance 1/24/2022
HealthInvest Partners AB Buys McKesson Corp, Cardinal Health Inc, AmerisourceBergen Corp, Sells ...
Yahoo Finance 1/18/2022
Advisors' Inner Circle Fund III Buys Washington Federal Inc, Supernus Pharmaceuticals Inc, ...
Yahoo Finance 12/28/2021
Trend Analysis & Forecast
Read more on this trend analysis & forecast here - uptrenddowntrend.com
Trendlast: 76.028
Financials
SUPN Income Statement
Annual
| Dec-12 | Dec-13 | Dec-14 | Dec-15 | Dec-16 | Dec-17 | Dec-18 | Dec-19 | Dec-20 | Dec-21 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | 1 M | 12 M | 122 M | 147 M | 215 M | 302 M | 409 M | 393 M | 520 M | 580 M |
| Cost of sales | -871000 | 362000 | 5 M | 7 M | 9 M | 8 M | 8 M | 13 M | 35 M | 39 M |
| Gross operating profit | 1 M | 11 M | 116 M | 139 M | 203 M | 287 M | 395 M | 378 M | 470 M | 507 M |
| Selling Gen & administrative expense | 20 M | 56 M | 72 M | 89 M | 106 M | 138 M | 155 M | 153 M | 201 M | 305 M |
| Research & development expense | 24 M | 17 M | 20 M | 29 M | 43 M | 50 M | 89 M | 69 M | 76 M | 90 M |
| Operating income | -42 M | -62 M | 24 M | 21 M | 54 M | 100 M | 144 M | 149 M | 176 M | 79 M |
| floaterest income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| floaterest expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other income net | -660000 | -23 M | 256000 | -2 M | -223000 | -219000 | 0 | -1 M | -2 M | 7 M |
| Pre-tax Income (EBT) | -46 M | -92 M | 20 M | 15 M | 50 M | 101 M | 140 M | 147 M | 169 M | 73 M |
| Income taxes | 0 | 0 | 630000 | 666000 | -41 M | 43 M | 29 M | 34 M | 42 M | 20 M |
| Net income from total operations | -46 M | -92 M | 20 M | 14 M | 91 M | 57 M | 111 M | 113 M | 127 M | 53 M |
| Minority floaterest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total net income | -46 M | -92 M | 20 M | 14 M | 91 M | 57 M | 111 M | 113 M | 127 M | 53 M |
| Preferred dividends | 1 M | 0 | 0 | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net income available for common | -47 M | -92 M | 20 M | 14 M | 91 M | 57 M | 111 M | 113 M | 127 M | 53 M |
| Depreciation | 871000 | 742000 | 928000 | 982000 | 3 M | 8 M | 5 M | 3 M | 15 M | 33 M |
| Amortization | 0 | 0 | 0 | 0 | 0 | 0 | 5 M | 5 M | 16 M | 30 M |
| Operating income before depreciation (EBITDA) | -42 M | -84 M | 26 M | 20 M | 58 M | 110 M | 165 M | 177 M | 211 M | 129 M |
| Total Income available for floaterest expense (EBIT) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Basic EPS total | -2.72 | -2.9 | 0.47 | 0.3 | 1.84 | 1.13 | 2.13 | 2.16 | 2.41 | 1.01 |
| Diluted EPS total | -2.72 | -2.9 | 0.32 | 0.28 | 1.76 | 1.08 | 2.05 | 2.1 | 2.36 | 0.98 |
Top MarketXLS Rank stocks
Call: 1-877-778-8358
I am so happy you are here. My name is Ankur and I am the founder/CEO of MarketXLS. Over the past four years, I have helped more than 2500 customers to implement their own investment research strategies and monitoring systems in Excel.
Get Access to 1 Billion Usable Market data points IN YOUR EXCEL SHEETS WITH EASY TO USE EXCEL FUNCTIONS
Get started today
Stand with Ukraine
As the situation in Ukraine escalates, many of us in MarketXLS are left with emotions too overwhelming to name. If you’d like to show your support, but aren’t sure how to, we want to help make it easier for you to act.
For any amount donated, we’ll extend your MarketXLS subscription for double of the donated amount. Please send proof of your payment to support@marketxls.com to avail the extention
From all of us at MarketXLS, thank you!